Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Fig. 1

Predictive value of FGF-23 for 2-year ISR risk. Comparison of FGF-23 expression between 2-year non-ISR patients and 2-year ISR patients (a). Ability of FGF-23 in predicting 2-year ISR risk in CHD patients treated by PCI with DES (b). FGF-23 fibroblast growth factor 23, ISR in-stent restenosis, PCI percutaneous coronary intervention, DES drug-eluting stent, CHD coronary heart disease, AUC area under the curve, CI confidence interval

Back to article page